Literature DB >> 3755785

The tissue localization of m-AMSA and its effect on thymidine incorporation in various tissues in vivo.

B Hellman, B S Andersson, P Slanina, A Mohammed, I Brandt, M Beran.   

Abstract

The distribution of 14C-labelled m-AMSA was studied in rats and pigmented mice using whole body autoradiography. The agent rapidly disappeared from the blood, accumulating in significant amounts in large parenchymal organs, certain endocrine tissues, and the retina of the pigmented mouse eye. The hemopoietic and lymphoid tissues showed a moderate uptake of radioactivity with the highest concentration observed in the thymus. The autoradiograms indicated a rapid excretion of radioactivity via the liver, kidney and the glandular part of the gastric mucosa. The distribution pattern of label from 14C-m-AMSA remained unaffected by pretreatment of animals with high dose (500 mg kg-1 b.w.) of cytosine arabinoside. Injection of unlabelled m-AMSA (7 mg kg-1 b.w.) to growing rats 24 h before sacrifice resulted in a highly significant (P less than 0.001) inhibition of 3H-thymidine incorporation into the DNA of thymus and spleen. A less pronounced reduction was observed in the kidney, adrenal, lung and testes. The thymidine incorporation into the DNA of bone marrow was markedly suppressed when calculated per dry weight, but increased when related to the DNA content, suggesting early regeneration of the remaining cells. In contrast, no significant effects were observed on the DNA synthesis in small intestine and liver.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3755785     DOI: 10.1007/bf02934559

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  36 in total

1.  Potential antitumor agents. 24. Dicationic analogues of the 4'-(9-acridinylamino)alkanesulfonanilides.

Authors:  G J Atwell; B F Cain; W A Denny
Journal:  J Med Chem       Date:  1977-09       Impact factor: 7.446

2.  The pharmacologic disposition of 4'-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats.

Authors:  R L Cysyk; D Shoemaker; R H Adamson
Journal:  Drug Metab Dispos       Date:  1977 Nov-Dec       Impact factor: 3.922

3.  An assessment of the immunosuppressive activity of the anti-tumour compound--4'-((9-acridinyl)amino)methanesulphon-m-anisidide (m-AMSA).

Authors:  G C Baguley; E M Falkenhaug; J M Rastrick; J Marbrook
Journal:  Eur J Cancer       Date:  1974-03       Impact factor: 9.162

4.  Accumulation of nicotine in pancreatic islets and calcitonin-producing cells in mice and chicks demonstrated by micro- and whole-body autoradiography.

Authors:  P Slanina; H Tjälve
Journal:  J Endocrinol       Date:  1973-07       Impact factor: 4.286

5.  Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992).

Authors:  S W Hall; J Friedman; S S Legha; R S Benjamin; J U Gutterman; T L Loo
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

6.  Potential antitumor agents. 20. Structure-activity-site relationships for the 4'(9-acridinylamino)alkanesulfonanilides.

Authors:  B F Cain; G J Atwell
Journal:  J Med Chem       Date:  1976-12       Impact factor: 7.446

7.  Potential antitumor agents. 17. 9-Anilino-10-methylacridinium salts.

Authors:  B F Cain; G J Atwell; W A Denny
Journal:  J Med Chem       Date:  1976-06       Impact factor: 7.446

8.  Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.

Authors:  S S Legha; M J Keating; K B McCredie; G P Bodey; E J Freireich
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

9.  Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.

Authors:  D A Van Echo; D F Chiuten; P E Gormley; J L Lichtenfeld; M Scoltock; P H Wiernik
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

10.  Amsacrine (AMSA).

Authors:  B F Issell
Journal:  Cancer Treat Rev       Date:  1980-06       Impact factor: 12.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.